Swedish Orphan Biovitrum's Partner Biogen Idec, Inc. (Massachusetts) To Present Phase 3 Data On Prolonged Half-Life Of Hemophilia Candidates In Young Children At Annual American Society of Hematology Meeting

Swedish Orphan Biovitrum AB's (publ ) (Sobi) partner Biogen Idec today announced that new data from their haemophilia clinical development and research programs will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), taking place in New Orleans, December 7-10. Researchers will discuss 10 abstracts covering the breadth of the company's comprehensive basic and clinical research programs. This includes new interim data from Phase 3 studies in paediatric populations evaluating the company's investigational long- lasting recombinant factor VIII Fc fusion protein candidate for haemophilia A and factor IX Fc fusion protein candidate for haemophilia B.

Help employers find you! Check out all the jobs and post your resume.